104 related articles for article (PubMed ID: 21192952)
41. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract][Full Text] [Related]
42. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint.
Yu CC; Hung SK; Liao HF; Lee CC; Lin HY; Lai HC; Li SC; Ho HC; Huang HB; Su YC
Anticancer Res; 2014 Jun; 34(6):2927-35. PubMed ID: 24922656
[TBL] [Abstract][Full Text] [Related]
43. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
Advani AS; Mahfouz RZ; Maciejewski J; Rybicki L; Sekeres M; Tripp B; Kalaycio M; Bates J; Saunthararajah Y
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):172-177.e1. PubMed ID: 24332215
[TBL] [Abstract][Full Text] [Related]
44. Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression.
Zhang L; Wang G; Wang L; Song C; Wang X; Kang J
Pharmazie; 2011 Aug; 66(8):614-8. PubMed ID: 21901986
[TBL] [Abstract][Full Text] [Related]
45. Isolation and structure of homotemsirolimuses A, B, and C.
Kong F; Zhu T; Yu K; Pagano TG; Desai P; Radebaugh G; Fawzi M
J Nat Prod; 2011 Apr; 74(4):547-53. PubMed ID: 21438579
[TBL] [Abstract][Full Text] [Related]
46. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Chou YW; Chaturvedi NK; Ouyang S; Lin FF; Kaushik D; Wang J; Kim I; Lin MF
Cancer Lett; 2011 Dec; 311(2):177-86. PubMed ID: 21862211
[TBL] [Abstract][Full Text] [Related]
48. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
Witt D; Burfeind P; von Hardenberg S; Opitz L; Salinas-Riester G; Bremmer F; Schweyer S; Thelen P; Neesen J; Kaulfuss S
Carcinogenesis; 2013 May; 34(5):1115-24. PubMed ID: 23349020
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Zhang P; Zhu X; Wu Y; Hu R; Li D; Du J; Jiao X; He X
Arch Biochem Biophys; 2016 Jan; 590():1-9. PubMed ID: 26558695
[TBL] [Abstract][Full Text] [Related]
50. HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines.
Martín-Sánchez E; Sánchez-Beato M; Rodríguez ME; Sánchez-Espiridión B; Gómez-Abad C; Bischoff JR; Piris MA; García-Orad A; García JF
Br J Haematol; 2011 Feb; 152(3):352-6. PubMed ID: 20955406
[No Abstract] [Full Text] [Related]
51. Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Peng ZH; Kopeček J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1928-33. PubMed ID: 24656564
[TBL] [Abstract][Full Text] [Related]
52. Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells.
Tsaur I; Makarević J; Juengel E; Gasser M; Waaga-Gasser AM; Kurosch M; Reiter M; Wedel S; Bartsch G; Haferkamp A; Wiesner C; Blaheta RA
Br J Cancer; 2012 Aug; 107(5):847-55. PubMed ID: 22782340
[TBL] [Abstract][Full Text] [Related]
53. Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.
Ji MM; Wang L; Zhan Q; Xue W; Zhao Y; Zhao X; Xu PP; Shen Y; Liu H; Janin A; Cheng S; Zhao WL
Autophagy; 2015; 11(12):2160-71. PubMed ID: 26735433
[TBL] [Abstract][Full Text] [Related]
54. Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation.
Gotfryd K; Skladchikova G; Lepekhin EA; Berezin V; Bock E; Walmod PS
BMC Cancer; 2010 Jul; 10():383. PubMed ID: 20663132
[TBL] [Abstract][Full Text] [Related]
55. Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms.
Fujii K; Suzuki N; Ikeda K; Hamada T; Yamamoto T; Kondo T; Iwatsuki K
J Proteomics; 2012 Feb; 75(4):1401-10. PubMed ID: 22123078
[TBL] [Abstract][Full Text] [Related]
56. Lysophosphatidic acid represses autophagy in prostate carcinoma cells.
Genc GE; Hipolito VEB; Botelho RJ; Gumuslu S
Biochem Cell Biol; 2019 Aug; 97(4):387-396. PubMed ID: 30403494
[TBL] [Abstract][Full Text] [Related]
57. mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.
Pool SE; Bison S; Koelewijn SJ; van der Graaf LM; Melis M; Krenning EP; de Jong M
Cancer Res; 2013 Jan; 73(1):12-8. PubMed ID: 23149918
[TBL] [Abstract][Full Text] [Related]
58. Are we missing the mTOR target in breast cancer?
Johnston SR
Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
[No Abstract] [Full Text] [Related]
59. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.
Schiewer MJ; Den R; Hoang DT; Augello MA; Lawrence YR; Dicker AP; Knudsen KE
Endocr Relat Cancer; 2012 Feb; 19(1):1-12. PubMed ID: 21903859
[TBL] [Abstract][Full Text] [Related]
60. Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Jiang W; Zheng Y; Huang Z; Wang M; Zhang Y; Wang Z; Jin X; Xia Q
Int Urol Nephrol; 2014 May; 46(5):941-6. PubMed ID: 24265041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
